Results 161 to 170 of about 57,365 (244)

Diagnostic potential of B‐cell translocation gene 2 in IgA nephropathy: Insights from molecular mechanisms

Journal of Cell Communication and Signaling, Volume 20, Issue 3, September 2026.
Diagnostic value of BTG2 and its immunoregulatory mechanism in IgAN. This study reveals that BTG2 improves immune microenvironment dysregulation, attenuates inflammation, and reduces fibrosis by promoting the expansion of T follicular helper cells, inducing macrophage polarization toward an M2 anti‐inflammatory phenotype, and inhibiting the TGF‐β1 ...
Min Kou, Mo Dan, Juan Cheng, Sheng Ge, Ruimin Ren   +4 more
wiley   +1 more source

Assessing α-galactosidase OmAGAL2 inhibitors and their impact on germination and sugar profiles in <i>Orobanche minor</i>. [PDF]

J Pestic Sci
Onitsuka M, Wakabayashi T, Ogawa T, Sugimoto Y, Ohta D, Okazawa A.   +5 more
europepmc   +1 more source

Cardiomyopathy associated with the Ala143Thr variant of the α-galactosidase A gene. [PDF]

Heart, 2020
Valtola K, Nino-Quintero J, Hedman M, Lottonen-Raikaslehto L, Laitinen T, Maria M, Kantola I, Naukkarinen A, Laakso M, Kuusisto J.   +9 more
europepmc   +1 more source

Impact of combined α-galactosidase and xylanase enzymes on growth performance, nutrients digestibility, chyme viscosity, and enzymes activity of broilers fed corn-soybean diets. [PDF]

J Anim Sci, 2021
Liu X, Xing K, Ning R, Carné S, Wu X, Nie W.   +5 more
europepmc   +1 more source

Occurrence of Infusion Associated Reactions and Antidrug Antibodies in Enzyme Replacement Therapy for Fabry Disease and the Effect of Preventive Measures

Journal of Inherited Metabolic Disease, Volume 49, Issue 5, September 2026.
Occurrence of infusion associated reactions and anti‐drug antibodies in enzyme replacement therapy for Fabry disease and the effect of preventive measures. ABSTRACT Male patients with the classical phenotype of Fabry disease (FD) are at risk of developing inhibiting antidrug antibodies (iADAs) against recombinant α‐galactosidase‐A, administered in the ...
Maud Janssens, Sanne J. van der Veen, Laura van Dussen, André B. P. van Kuilenburg, Marion M. M. G. Brands, Mirjam Langeveld   +5 more
wiley   +1 more source

Optimizing α-galactosidase A enzyme cutoff for Fabry disease screening in chronic kidney disease patients: a single-center reassessment of diagnostic yield and cost-effectiveness. [PDF]

Ren Fail
Tsai SF, Wu MJ, Hsieh HH, Chen CH.
europepmc   +1 more source

Characterization of Adult Patients With Neurometabolic Disorders: A Cross‐Sectional Study at a Tertiary Neurology Center in Sweden

JIMD Reports, Volume 67, Issue 5, September 2026.
ABSTRACT Adult patients with inherited metabolic diseases are often overlooked. Limited data on this population hinder adequate planning of their clinical and social care. In this retrospective, observational, cross‐sectional service evaluation study, we reviewed the electronic medical records of adult patients with inherited neurometabolic diseases ...
Boel Ernerdahl, Ashraf Yahia, Andreas Puschmann   +2 more
wiley   +1 more source

New α-galactosidase-inhibiting aminohydroxycyclopentanes. [PDF]

RSC Adv, 2021
Weber P, Fischer R, Nasseri SA, Stütz AE, Thonhofer M, Withers SG, Wolfsgruber A, Wrodnigg TM.   +7 more
europepmc   +1 more source

Ferroptosis: Newly Emerged Regulator for Human Disease

MedComm, Volume 7, Issue 9, September 2026.
Ferroptosis is a key regulated cell death pathway closely involved in cancers, neurodegenerative disorders, acute organ injuries, and cardiovascular and chronic metabolic diseases, representing a promising therapeutic target for diverse human illnesses.
Dandan Xiao, Lin Ye, Tianqi Jiang, Mengyuan Liu, Yuxia Zhou   +4 more
wiley   +1 more source

Silencing of the Alkaline α-Galactosidase Gene <i>CsAGA1</i> Impairs Root and Gall Development in Cucumber upon <i>Meloidogyne incognita</i> Infection. [PDF]

Int J Mol Sci
Ji T, Wang X, Wang X, Gao L, Tian Y, Ma S.   +5 more
europepmc   +1 more source